SynthesisGut and liver2021
Diagnostic Accuracy of Fecal Calprotectin for the Detection of Small Bowel Crohn's Disease through Capsule Endoscopy: An Updated Meta-Analysis and Systematic Review.
Synthesis in Gut and liver, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Diagnostic Utility of Non-invasive Tests for Inflammatory Bowel Disease: An Umbrella Review.Frontiers in medicine · 2022Pooled it
- Interpreting Biomarker Discordance in Inflammatory Bowel Disease: Beyond Fecal Calprotectin and C-Reactive Protein.Biomedicines · 2026Review
- Capsule Endoscopy in Inflammatory Bowel Disease: Current Status and Issues in Clinical Practice.DEN open · 2026Review
- Comparing the accuracy of computed tomography enterography to balloon-assisted enteroscopy in the evaluation of small bowel Crohn's disease.Journal of the Canadian Association of Gastroenterology · 2026Article
- Fecal Calprotectin and Segmental Inflammation in Small Bowel Crohn's Disease: A Capsule Endoscopy-Based Study.Biomedicines · 2025Article
- Validating Simple Modifications to the Rome IV Criteria for the Diagnosis of Irritable Bowel Syndrome in Secondary Care.Alimentary pharmacology & therapeutics · 2025Article
- Markers of Intestinal Permeability and Inflammation in Enterally Fed Children with Cerebral Palsy.Nutrients · 2024Article
- Diagnostic Procedures for Inflammatory Bowel Disease: Laboratory, Endoscopy, Pathology, Imaging, and Beyond.Diagnostics (Basel, Switzerland) · 2024Review
- Current Approaches for Monitoring of Patients with Inflammatory Bowel Diseases: A Narrative Review.Journal of clinical medicine · 2024Review
- Clinical Value of Detecting Fecal Calprotectin by Using Colloidal Gold Assay in Screening or Diagnosing Crohn's Disease.Gastroenterology research and practice · 2023Article
- Fecal Calprotectin for Small Bowel Crohn's Disease: Is It a Cutoff Issue?Diagnostics (Basel, Switzerland) · 2022Article
- Small intestinal bacterial overgrowth is associated with clinical relapse in patients with quiescent Crohn's disease: a retrospective cohort study.Annals of translational medicine · 2022Article
- Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease.Alimentary pharmacology & therapeutics · 2022Article
- Gut dysbiosis associated with worse disease activity and physical function in axial spondyloarthritis.Arthritis research & therapy · 2022Article
- Capsule Endoscopy in Inflammatory Bowel Disease: When? To Whom?Diagnostics (Basel, Switzerland) · 2021Review
- Small-Bowel Capsule Endoscopy-Optimizing Capsule Endoscopy in Clinical Practice.Diagnostics (Basel, Switzerland) · 2021Review
- Optimal Cutoff Level of Fecal Calprotectin for Detecting Small Bowel Inflammation in Crohn's Disease.Gut and liver · 2021Article
- Expert recommendations regarding the use of fecal calprotectin in daily clinical practice: statements of a taskforce process from the Hellenic Group for the Study of Inflammatory Bowel Disease (EOMIFNE).Annals of gastroenterologyArticle
- Beyond Inflammatory Bowel Disease: Calprotectin as a Marker for Trichobezoar? A Case Report.Case reports in gastroenterologyArticle
- Fecal calprotectin as an inflammatory biomarker in small bowel Crohn disease.Porto biomedical journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aims: The diagnosis of small bowel Crohn's disease with negative ileocolonoscopic findings has been challenging. Fecal calprotectin (FC) has been used to detect colonic inflammation, but its efficacy for detecting small bowel inflammation is less established. We performed an updated meta-analysis to evaluate the diagnostic accuracy of FC to detect active small bowel inflammation observed during capsule endoscopy. Methods: We conducted a systematic literature search for studies that evaluated the correlation between small bowel inflammation and FC in patients with suspected/established Crohn's disease. We calculated the pooled sensitivity, specificity, and diagnostic odds ratios (DORs) and constructed hierarchical summary receiver operating characteristic curves for FC cutoffs of 50, 100, and 200 μg/g. Results: Fourteen studies were eligible for the final analysis. The DORs of all FC cutoffs were significant. The highest DOR was observed at 100 μg/g (sensitivity, 0.73; specificity, 0.73; and DOR, 7.89) and was suggested as the optimal diagnostic cutoff. If we analyzed only studies that included patients with suspected Crohn's disease, the DOR was 8.96. If we analyzed only studies that included patients with a Lewis score ≥135 as a diagnostic criterion for active disease, the DOR was 10.90. Conclusions: FC has significant diagnostic accuracy for detecting small bowel inflammation, and an FC cutoff of 100 μg/g can be used as a tool to screen for small bowel Crohn's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.